Bronchitis Treatment Global Market Report 2024

The bronchitis treatment market size has grown strongly in recent years. It will grow from $5.25 billion in 2023 to $5.58 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth observed in the historical period can be attributed to several factors, including the escalation of air pollution levels, the widespread epidemic of cigarette smoking, a rise in respiratory infections, environmental and occupational exposures, as well as various lifestyle factors contributing to respiratory issues.

The bronchitis treatment market size is expected to see strong growth in the next few years. It will grow to $7.27 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. Anticipated growth in the upcoming period can be attributed to several factors, including advancements in respiratory medicine, increased access to vaccination, customized treatment approaches for pediatric patients, the implementation of precision medicine in respiratory care, and global initiatives aimed at reducing smoking prevalence. Key trends expected in the forecast period encompass personalized treatment approaches tailored to individual patients, advancements in inhalation therapies, the development of targeted therapies catering to specific types of bronchitis, a focus on prevention strategies including vaccination, and the adoption of patient-centric care models in respiratory healthcare.

The anticipated rise in the prevalence of respiratory diseases is expected to drive the growth of the bronchitis treatment market in the future. Respiratory diseases encompass conditions affecting the lungs and the broader respiratory system, stemming from various factors such as infections, allergens, irritants, and genetic predispositions. The treatment for bronchitis, a common respiratory ailment, involves diverse approaches tailored to the specific root cause and severity of the condition. Treatment options include antibiotics, anti-inflammatories, and bronchodilators designed to open the airways of respiratory organs. Notably, in June 2023, reports from the Australian Institute of Health and Welfare revealed an increase in respiratory disease-related deaths in Australia, reaching 46,551 in 2021. Additionally, data from The Lancet indicated a 9.50% rise in new cases of respiratory syncytial virus (RSV) during the summer of 2021. These findings underscore the driving force of the growing incidence of respiratory diseases on the bronchitis treatment market.

The growing aging population is poised to contribute to the expansion of the bronchitis treatment market. The aging population phenomenon, characterized by an increasing proportion of elderly individuals within a population, presents a demographic shift with implications for healthcare. Bronchitis treatment in the elderly offers various advantages, addressing both acute and chronic forms of the condition. Benefits include symptom alleviation, complication prevention, improved respiratory function, enhanced ease of breathing, elevated overall quality of life, and reduced hospitalization risks. Globally, the World Health Organization projects that by 2030, 1 in 6 people will be aged 60 or older, with the number doubling to 2.1 billion individuals by 2050. In the UK, the House of Commons Library forecasts a 24% rise in the senior population, reaching 17.4 million people by 2043. The increasing aging population emerges as a significant driver for the growth of the bronchitis treatment market.

A prominent trend gaining traction in the bronchitis treatment market is product innovation, with major companies adopting new technologies to bolster their market standing. Notably, in June 2021, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, introduced the first generic version of PERFOROMIST®, a formoterol fumarate inhalation solution. This innovative solution targets bronchoconstriction in individuals with chronic obstructive pulmonary disease (COPD), encompassing chronic bronchitis and emphysema. Adults with COPD can manage their symptoms using this long-acting beta2-adrenergic agonist (LABA) delivered through a nebulizer. The introduction of such advanced products highlights the significance of product innovations in sustaining competitiveness within the bronchitis treatment market.

Leading companies in the bronchitis treatment market are strategically emphasizing innovative products such as arformoterol tartrate to enhance their market revenues. Arformoterol tartrate is a medication designed for treating bronchoconstriction in individuals with emphysema and chronic bronchitis, specifically those diagnosed with chronic obstructive pulmonary disease (COPD). Lupin Limited, an India-based pharmaceutical company, exemplifies this strategy by launching arformoterol tartrate in June 2021. As a bronchodilator belonging to the long-acting beta-agonist (LABA) medication class, it functions by inducing relaxation in the muscles surrounding the airways, facilitating improved breathing. Administered through nebulization, this inhalation solution is typically used twice daily - in the morning and evening.

In January 2022, Covis Pharma Group, a Switzerland-based specialty pharmaceutical company, made a strategic move by acquiring the respiratory portfolio of two medicines from AstraZeneca for $270 million. This transaction involved the acquisition of Eklira and Duaklir, positioning Covis to offer a comprehensive range of best-in-class treatments for allergic rhinitis, asthma, and chronic obstructive pulmonary disease (COPD). The acquisition underscores Covis Pharma Group's capability to collaborate effectively and become a preferred partner for major pharmaceutical firms. AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company and a co-developer of a vaccine against bronchiolitis, is the other party involved in this significant transaction. This strategic initiative demonstrates the ongoing efforts of major companies to expand their product portfolios and strengthen their positions in the competitive bronchitis treatment market.

Major companies operating in the bronchitis treatment market report are AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Dr. Reddy’s Laboratories, Melinta Therapeutics LLC, Sanofi S.A., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Cipla Inc., Merck and Co. Inc., Bayer AG, Johnson & Johnson Private Limited, Viatris Inc., Lupin Ltd., Cadila Healthcare Limited, Lincoln Pharmaceuticals Ltd., Nephron Pharmaceuticals Corporation, Apotex Inc., Mylan N.V., Eli Lilly and Company, AbbVie, Hetero Healthcare Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Alkem Laboratories Ltd., Wockhardt Ltd.

North America was the largest region in the bronchitis treatment market in 2023. The regions covered in the bronchitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bronchitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The treatment is designed to address both acute and chronic bronchitis, utilizing various approaches such as medications and oxygen therapy. Acute bronchitis is a contagious viral infection leading to inflammation in the bronchial tubes. These treatments are typically available through diverse distribution channels such as online pharmaceutical stores, retail pharmacies, and hospital pharmacies.

The bronchitis treatment market research report is one of a series of new reports that provides bronchitis treatment market statistics, including bronchitis treatment industry global market size, regional shares, competitors with a bronchitis treatment market share, detailed bronchitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the bronchitis treatment industry. This bronchitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.